Lightning Round: Huntington Ingalls is a buy, says Jim Cramer
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth
July 11 -Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price target to $1,100 and citing strong momentum in the company's obesity treatment portfolio Analyst Chris Schott pointed to continued strength in sales of Mounjaro and Zepbound, with the latter accounting for roughly 75% of new treatment starts despite its removal from CVS Health's (CVS) preferred drug list. JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in the category. The brokerage sees long-term growth potential driven by next-gen drugs, including orforglipron, a pill-based GLP-1 treatment in development, and the late-stage candidate retatrutide, referred to as Triple G. Patent coverage into the 2030s reduces risk of near-term exclusivity losses, the note said, adding that earnings could surpass $55 per share by 2030, up from $13 in 2023. Strong pipeline momentum and durable patent coverage continue to bolster investor confidence. Based on the one year price targets offered by 26 analysts, the average target price for Eli Lilly and Co is $967.78 with a high estimate of $1190.00 and a low estimate of $675.00. The average target implies a upside of +22.40% from the current price of $790.65. Based on GuruFocus estimates, the estimated GF Value for Eli Lilly and Co in one year is $1218.37, suggesting a upside of +54.10% from the current price of $790.65. Gf value is Gurufocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. For deeper insights, visit the forecast page. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Wall Street Bets Big on Eli Lilly: New Drugs Could Drive 300% EPS Growth
July 11 -Eli Lilly (NYSE:LLY) drew attention on Friday after JPMorgan reiterated its bullish stance on the stock, raising its price target to $1,100 and citing strong momentum in the company's obesity treatment portfolio Analyst Chris Schott pointed to continued strength in sales of Mounjaro and Zepbound, with the latter accounting for roughly 75% of new treatment starts despite its removal from CVS Health's (CVS) preferred drug list. JPMorgan said Eli Lilly is enrolling about 500,000 new obesity drug patients per month, and maintains more than 60% share in the category. The brokerage sees long-term growth potential driven by next-gen drugs, including orforglipron, a pill-based GLP-1 treatment in development, and the late-stage candidate retatrutide, referred to as Triple G. Patent coverage into the 2030s reduces risk of near-term exclusivity losses, the note said, adding that earnings could surpass $55 per share by 2030, up from $13 in 2023. Strong pipeline momentum and durable patent coverage continue to bolster investor confidence. Based on the one year price targets offered by 26 analysts, the average target price for Eli Lilly and Co is $967.78 with a high estimate of $1190.00 and a low estimate of $675.00. The average target implies a upside of +22.40% from the current price of $790.65. Based on GuruFocus estimates, the estimated GF Value for Eli Lilly and Co in one year is $1218.37, suggesting a upside of +54.10% from the current price of $790.65. Gf value is Gurufocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. For deeper insights, visit the forecast page. This article first appeared on GuruFocus.
Yahoo
12 hours ago
- Yahoo
UnitedHealth Group Incorporated (UNH): 'Medicare Fraud Is Prison,' Warns Jim Cramer
We recently published . UnitedHealth Group Incorporated (NYSE:UNH) is one of the stocks Jim Cramer recently discussed. UnitedHealth Group Incorporated (NYSE:UNH) is the largest healthcare benefits provider in America. It is also one of the worst-performing stocks in 2025 as the shares have lost 40% year-to-date. UnitedHealth Group Incorporated (NYSE:UNH)'s shares sank by a massive 27.3% in April after the firm stunned investors by missing analyst estimates for its latest quarter. Cramer's recent remarks about the firm discussed media reports of impropriety and pointed out that UnitedHealth Group Incorporated (NYSE:UNH) wouldn't be buying shares if they were true. However, this time, he had a much darker tone: '[On a WSJ report that UNH deploys doctors and nurses to gather diagnoses that bolster its payments with UNH responding that it welcomes reviews] Well I'm glad they welcome it but I do want to caution them, and I think I happen to like this CEO very much, but Medicare fraud is prison. It's not, hey listen we'll slap UNH on the wrist. It's prison. And it's probably the most I think easily, the crimes are easily followed and the judgement is swift. The reason why people are so focused on this is that it's not a fine.' Previously, the CNBC host discussed UnitedHealth Group Incorporated (NYSE:UNH) in detail: 'The third worst performer was, wow, UnitedHealth Group, suddenly very troubled managed care company that used to be the ultimate darling in the group. It's down 38% in the first half. UnitedHealth's troubles are very well documented. I'm not even talking about the assassination last December, as terrible as that was. The real trouble started in April when the company reported a weak quarter, dragged down by high utilization rates, meaning people are getting much more healthcare than UNH… needs to pay for. A senior healthcare professional giving advice to a patient in a clinic. What's starting to become clear is that the company made some major missteps with its underwriting, especially with Medicare Advantage plans for seniors. They're far from the only one in the industry with this problem, but UNH might be the hardest hit. This is the largest player in the Medicare Advantage space with the most extensive data, and they really should have been able to avoid these mistakes. They almost always have, but clearly, they didn't. The company made a change in the top mid-May with CEO Andrew Witty stepping down for personal reasons. Turning around UNH is now the job of Stephen Hemsley, whom I really like. He was previously CEO from 2006 to 2017. And there's some nascent optimism that he can get this business back on track, but I don't necessarily think this will happen quickly. If you're inclined to bet on a UNH comeback, I suggest that you take it slowly because you got all the time in the world. You actually might even want to wait to see the next quarter, which could be what we call a clearing event for the negatives.' While we acknowledge the potential of UNH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
